Rasagiline
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
- Rasagiline
- Rasagiline: From Parkinson's Disease (MAO‑B Inhibition) to PLA2G6‑Associated Neurodegeneration
Rasagiline: From Parkinson's Disease (MAO‑B Inhibition) to PLA2G6‑Associated Neurodegeneration
One-Sentence Summary
Rasagiline's original indication is not recorded in the current dataset, though it is clinically known as a selective, irreversible MAO‑B inhibitor used in Parkinson's disease. The TxGNN model's top prediction is PLA2G6‑Associated Neurodegeneration, a rare neurodegenerative disorder with a parkinsonism phenotype. This is a pure computational prediction — 0 clinical trials and 0 publications currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this dataset (data gap). Clinically known use: MAO‑B inhibitor therapy in Parkinson's disease |
| Predicted New Indication | PLA2G6-Associated Neurodegeneration |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this dataset (marked as a High-severity data gap). Based on general pharmacological knowledge referenced within the evidence pack itself, Rasagiline is a selective, irreversible MAO‑B inhibitor, a drug class established for reducing dopamine breakdown and providing neuroprotection in Parkinson's disease.
The top-ranked candidate, PLA2G6‑Associated Neurodegeneration (PLAN), has an adult-onset subtype (PARK14) that presents with dystonia‑parkinsonism and basal ganglia dopaminergic degeneration. This creates a plausible, though purely theoretical, mechanistic bridge: reduced dopamine catabolism via MAO‑B inhibition could in principle offer symptomatic or neuroprotective benefit in this parkinsonism-spectrum phenotype.
It is important to note this mechanistic link has no dedicated clinical trial or literature support — it is inferred by TxGNN from network structure and general disease-class similarity, not from any direct evidence of efficacy in PLAN.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Rasagiline is not currently marketed in Norway, and no marketing authorization records are available in this dataset (0 licenses).
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA labeling data (warnings and contraindications) is currently a blocking data gap and has not been reviewed — no formal safety (S1) assessment can be completed until this is resolved.
Other Predicted Indications (For Context)
The evidence pack includes 5 additional TxGNN candidates, all at evidence level L5 with no supporting trials or literature:
| Rank | Disease | TxGNN Score | Mechanistic Plausibility | Recommendation |
|---|---|---|---|---|
| 2 | Rasmussen subacute encephalitis | 99.56% | None (autoimmune/inflammatory, unrelated to MAO‑B pathway) | Hold |
| 3 | Myelitis | 99.32% | None (inflammatory/infectious spinal cord disease) | Hold |
| 4 | Paralysis agitans, juvenile, of Hunt | 99.25% | Strong — historical term for juvenile parkinsonism, same disease spectrum as Rasagiline's known use | Research Question |
| 5 | Transaldolase deficiency | 99.19% | None (pentose phosphate pathway defect) | Hold |
| 6 | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99.01% | None (structural developmental brain malformation) | Hold |
Rank 4 ("Hunt's juvenile paralysis agitans") is mechanistically the most coherent candidate, since it falls within the same parkinsonism spectrum as Rasagiline's established pharmacology, but it lacks any subtype-specific trial or case-report evidence and remains a research hypothesis only.
Conclusion and Next Steps
Decision: Hold
Rationale: All six predicted indications are at evidence level L5 (model prediction only, no clinical or literature support). In addition, TFDA safety labeling data is a blocking gap, preventing any formal safety review, and the drug is not marketed in Norway.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) to resolve the blocking safety data gap (DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- Original indication history for the drug (currently missing from dataset)
- Preclinical or mechanistic studies specifically addressing MAO‑B inhibition in PLAN or juvenile parkinsonism-spectrum disorders before advancing beyond hypothesis stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.